. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Muscle Nerve. 2019 Jul 18;60(3):292–298. doi: 10.1002/mus.26625

Table 2.

Association between change from baseline post-dose CMAP amplitude and change from baseline post-dose 3TUG

Group	Continuous DAP		Withdrew from DAP
Model^*	Effect estimate (95% CI)	P-value	Effect estimate (95% CI)	P-value
Day 3^†	−0.70 (−3.33, 1.92)	0.55	−0.01 (−2.20, 2.18)	0.99
Day 4^‡	−0.43 (−1.65, 0.79)	0.43	−1.05 (−1.52, −0.57)	<0.01
Day 5^§	0.32 (−1.69, 2.32)	0.71	−0.52 (−1.59, 0.56)	0.29

ΔCMAP_i = Δ3TUG_i

^†

continued DAP N=10, withdrawn from DAP N=14;

^‡

continued DAP N=9, withdrawn from DAP N=12;

^§

continued DAP N=8, withdrawn from DAP N=8. Only 3TUG-CMAP pairs with CMAPs considered acceptable by the blinded reviewer were included in the analysis for each day

CMAP, compound muscle action potential; 3TUG, triple timed-up-and-go test; DAP, 3,4-diaminopyridine free base